J Liver Cancer.  2023 Mar;23(1):121-123. 10.17998/jlc.2023.3.10.

How to optimize the treatment strategy for advanced-stage hepatocellular carcinoma with macrovascular invasion

• Kim BK

• KMID: 2540824
• DOI: http://doi.org/10.17998/jlc.2023.3.10

Reference

References

1. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, GarciaCriado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022; 76:681–693.

2. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382:1894–1905.

3. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC). 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28:583–705.

4. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67:358–380.

5. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76:862–873.

6. Martelletti C, Ricotti A, Gesualdo M, Carucci P, Gaia S, Rolle E, et al. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score and Bayesian analysis. J Dig Dis. 2021; 22:496–502.

7. Kim J, Byun HK, Kim TH, Kim SI, Kim BK, Kim SU, et al. Liverdirected concurrent chemoradiotherapy versus sorafenib in hepatocellular carcinoma with portal vein tumor thrombosis. Cancers (Basel). 2022; 14:2396.

8. Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, et al. Appraisal of long-term outcomes of liver-directed concurrent chemoradiotherapy for hepatocellular carcinoma with major portal vein invasion. J Hepatocell Carcinoma. 2020; 7:403–412.

9. Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, et al. Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys. 2020; 107:106–115.

10. Jun CH, Yoon JH, Cho E, Shin SS, Cho SB, Kim HJ, et al. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: a novel approach to subclassification and treatment. Medicine (Baltimore). 2017; 96:e6745.

11. Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015; 10:e0124434.

12. Lee S, Kim BK, Song K, Park JY, Ahn SH, Kim SU, et al. Subclassification of Barcelona clinic liver cancer B and C hepatocellular carcinoma: a cohort study of the multicenter registry database. J Gastroenterol Hepatol. 2016; 31:842–847.

13. Jin S, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, et al. Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment. J Liver Cancer. 2023; 23:177–188.

14. Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2023; 180:9–20.

15. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial. Lancet. 2018; 391:1163–1173.